An evaluation of palbociclib as a breast cancer treatment option: a current update. (11th February 2021)

• Record Type: Journal Article
• Authors: Gallanis, Gregory T.; Pericas, Ramon I.; Riegel, Anna T.; Pohlmann, Paula R.
• Is Part Of: Expert opinion on pharmacotherapy. Volume 22:Number 3(2021)
• Page Start: 281
• Page End: 290
• Publication Date: 2021-02-11
• Subjects: Adjuvant therapy -- breast cancer -- CDK4/6 inhibitors -- clinical trials -- metastatic breast cancer -- neoadjuvant therapy -- palbociclib -- triple-negative breast cancer -- HER2-positive breast cancer -- HR+HER2- breast cancer; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2020.1838485
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: Patients with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer have benefitted from treatment with palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor capable of selectively targeting mechanisms of cell cycle progression that contribute to tumor cell proliferation. Palbociclib use in this setting demonstrates improved progression-free survival when given in combination with aromatase inhibitors or fulvestrant. Areas covered: The authors describe the current state of research surrounding palbociclib use in breast cancer, present evidence supporting a role for palbociclib in additional subtypes of metastatic breast cancer such as HER2-positive (HER2+) and triple-negative, report ongoing clinical trials aimed at expanding the scope of use for palbociclib, and discuss expected clinical results that will better inform decisions on including palbociclib as a part of breast cancer treatment strategies. Expert opinion: Preclinical and clinical studies have shown promising evidence for palbociclib use in metastatic HER2+ and androgen receptor-expressing triple-negative breast cancer but mixed results in the adjuvant/neoadjuvant setting, where differences may only be detectable in high-risk disease. Palbociclib combinations may constitute viable replacements for chemotherapy in the neoadjuvant setting as part of de-escalation strategies. Investigation into synergy of palbociclib with immunotherapies is also ongoing based on non-canonical effects of CDK4/6 inhibition on the tumor immune microenvironment.